Compositions comprising an anti-C5 antibody
The present application relates to methods and compositions employing an antibody that inhibits activation of the complement system and can be used to prevent or treat a pulmonary disease or condition.
1. A pharmaceutical composition comprising 30 mg/mL of an anti-C5 antibody, sodium phosphate at a concentration of 10 mM, sodium chloride at a concentration of 150 mM, and polysorbate 80 at a level of 0.001 to 0.02% by volume, wherein the anti-C5 antibody comprises a variable light chain CDR1 comprising amino acid residues 26-36 of SEQ ID NO:1, a variable light chain CDR2 comprising amino acid residues 52-58 of SEQ ID NO:1, a variable light chain CDR3 comprising amino acid residues 91-99 of SEQ ID NO:1, a variable heavy chain CDR1 comprising amino acid residues 152-161 of SEQ ID NO:1, a variable heavy chain CDR2 comprising amino acid residues 176-192 of SEQ ID NO:1, and a variable heavy chain CDR3 comprising amino acid residues 225-237 of SEQ ID NO:1, and wherein the pH of the composition is between pH 6 and pH 8.
2. A pharmaceutical composition comprising 30 mg/mL of an anti-C5 antibody, sodium phosphate at a concentration of 10 mM, sodium chloride at a concentration of 150 mM, and polysorbate 80 at a level of 0.001 to 0.02% by volume, wherein the anti-C5 antibody comprises a heavy chain variable region comprising residue numbers 1-122 of SEQ ID NO: 2 and a light chain variable region comprising residue numbers 1-108 of SEQ ID NO: 3, and wherein the pH of the composition is between pH 6 and pH 8.
3. The pharmaceutical composition of claim 1 , wherein the composition has physiologic osmolality.
4. The pharmaceutical composition of claim 2 , wherein the composition has physiologic osmolality.